Endocrine disorders in Fanconi anemia: Recommendations for screening and treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 3, 2015, Pages 803-811

  Petryk, Anna ^a   Shankar, Roopa Kanakatti ^b   Giri, Neelam ^c   Hollenberg, Anthony N ^d   Rutter, Meilan M ^e   Nathan, Brandon ^a   Lodish, Maya ^f,g   Alter, Blanche P ^c   Stratakis, Constantine A ^g   Rose, Susan R ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GLUCOSE; GONADORELIN AGONIST; GROWTH HORMONE; INSULIN; MEDROXYPROGESTERONE; VITAMIN D; HUMAN GROWTH HORMONE;

BODY MASS; BONE MINERALIZATION; CALCIUM INTAKE; DISEASE ASSOCIATION; DYSLIPIDEMIA; EARLY DIAGNOSIS; EARLY INTERVENTION; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; FANCONI ANEMIA; GONADAL DISEASE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOPHYSIS DISEASE; HYPOTHYROIDISM; LIPID METABOLISM; MALNUTRITION; MEDICAL LITERATURE; OBESITY; PATIENT ASSESSMENT; PATIENT CARE; PATIENT COUNSELING; PRIORITY JOURNAL; PUBERTY DISORDERS; PUBLICATION; REVIEW; SCREENING TEST; THYROID FUNCTION TEST; TREATMENT INDICATION; VITAMIN INTAKE; ADULT; BODY WEIGHT; CHILD; COMPLICATION; DEFICIENCY; ENDOCRINE SYSTEM DISEASES; GLUCOSE METABOLISM DISORDERS; GROWTH DISORDERS; MASS SCREENING; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

ADULT; CHILD; ENDOCRINE SYSTEM DISEASES; FANCONI ANEMIA; GLUCOSE METABOLISM DISORDERS; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; MALNUTRITION; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; THINNESS;

EID: 84925011344     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4357     Document Type: Review

References (83)

1. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009;668:4-10.
2. Rose SR, Myers KC, Rutter MM, et al. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer. 2012;59:690-696.
3. Giri N, Batista DL, Alter BP, Stratakis CA. Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab. 2007;92:2624-2631.
4. Wajnrajch MP, Gertner JM, Huma Z, et al. Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. Pediatrics. 2001;107:744-754.
5. Lindberg MK, Vandenput L, Movèrare Skrtic S, et al. Androgens and the skeleton. Minerva Endocrinol. 2005;30:15-25.
6. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am. 1996;25:699-717.
7. Keenan BS, Richards GE, Ponder SW, Dallas JS, Nagamani M, Smith ER. Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulinlike growth factor-I in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab. 1993;76:996-1001.
8. Allen DB, Cuttler L. Clinical practice. Short stature in childhood-challenges and choices. N Engl J Med. 2013;368:1220-1228.
9. Ranke MB, Schwarze CP, Dopfer R, et al. Late effects after stem cell transplantation (SCT) in children-growth and hormones. Bone Marrow Transplant. 2005;35(suppl 1):S77-S81.
10. Pochedly C, Collipp PJ, Wolman SR, Suwansirikul S, Rezvani I. Fanconi's anemia with growth hormone deficiency. J Pediatr. 1971;79:93-96.
11. Aynsley-Green A, Zachmann M, Werder EA, Illig R, Prader A. Endocrine studies in Fanconi's anaemia. Report of 4 cases. Arch Dis Child. 1978;53:126-131.
12. Zachmann M, Illig R, Prader A. Fanconi's anemia with isolated growth hormone deficiency. J Pediatr. 1972;80:159-160.
13. Nordan UZ, Humbert JR, MacGillivray MH, Fitzpatrick JE. Fanconi's anemia with growth hormone deficiency. Am J Dis Child. 1979;133:291-293.
14. Dupuis-Girod S, Gluckman E, Souberbielle JC, Brauner R. Growth hormone deficiency caused by pituitary stalk interruption in Fanconi's anemia. J Pediatr. 2001;138:129-133.
15. Nunez SB, Municchi G, Barnes KM, Rose SR. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 concentrations compared to stimulated and night growth hormone in the evaluation of short children-a clinical research center study. J Clin Endocrinol Metab. 1996;81:1927-1932.
16. Marin G, Domené HM, Barnes KM, Blackwell BJ, Cassorla FG, Cutler GB Jr. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab. 1994;79:537-541.
17. Martínez AS, Domené HM, Ropelato MG, et al. Estrogen priming effect on growth hormone(GH)provocative test: a useful tool for the diagnosis of GH deficiency. J Clin Endocrinol Metab. 2000;85:4168-4172.
18. Petryk A, Baker KS, Frohnert B, et al. Blunted response to a growth hormone stimulation test is associated with unfavorable cardiovascular risk factor profile in childhood cancer survivors. Pediatr Blood Cancer. 2013;60:467-473.
19. Kargi AY, Merriam GR. Testing for growth hormone deficiency in adults: doing without growth hormone-releasing hormone. Curr Opin Endocrinol Diabetes Obes. 2012;19:300-305.
20. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85:3990-3993.
21. Forlenza GP, Polgreen LE, Miller BS, MacMillan ML, Wagner JE, Petryk A. Growth hormone treatment of patients with Fanconi anemia after hematopoietic cell transplantation. Pediatr Blood Cancer. 2014;61:1142-1143.
22. Swift M. Fanconi's anaemia in the genetics of neoplasia. Nature. 1971;230:370-373.
23. Auerbach AD, Allen RG. Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. Cancer Genet Cytogenet. 1991;51:1-12.
24. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood. 1994;84:1650-1655.
25. Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res. 2007;68(suppl 5):41-47.
26. Kemp SF, Kuntze J, Attie KM, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab. 2005;90:5247-5253.
27. Quigley CA, Gill AM, Crowe BJ, et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J Clin Endocrinol Metab. 2005;90:5188-5196.
28. Bowlby DA, Rapaport R. Safety and efficacy of growth hormone therapy in childhood. Pediatr Endocrinol Rev. 2004;2(suppl 1):68-77.
29. Harris M, Hofman PL, Cutfield WS. Growth hormone treatment in children: review of safety and efficacy. Paediatr Drugs. 2004;6:93-106.
30. Gibney J, Johannsson G. Safety of growth hormone replacement therapy in adults. Expert Opin Drug Saf. 2004;3:305-316.
31. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91:3494-3498.
32. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87:3136-3141.
33. Patterson BC, Chen Y, Sklar CA, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2014;99:2030-2037.
34. Pekic S, Popovic V. GH therapy and cancer risk in hypopituitarism: what we know from human studies. Eur J Endocrinol. 2013;169:R89-R97.
35. Woodmansee WW, Zimmermann AG, Child CJ, et al. Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol. 2013;168:565-573.
36. Hartman ML, Xu R, Crowe BJ, et al. Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab. 2013;98:980-988.
37. Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM, Brabant G. Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab. 2011;96:2756-2761.
38. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95:167-177.
39. Poidvin A, Touzé E, Ecosse E, et al. Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology. 2014;83:780-786.
40. Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97:416-425.
41. Erfurth EM. Update in mortality in GH-treated patients. J Clin Endocrinol Metab. 2013;98:4219-4226.
42. Sävendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97:E213-E217.
43. van Bunderen CC, van Varsseveld NC, Erfurth EM, Ket JC, Drent ML. Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin Endocrinol (Oxf). 2014;81:1-14.
44. Hindmarsh PC, Peters CJ. Growth hormone treatment and stroke: should we be concerned? A case for cohort studies [published online September 10, 2014]. Clin Endocrinol (Oxf). doi: 10.1111/cen.12611.
45. Malozowski S. Reports of increased mortality and GH: will this affect current clinical practice? J Clin Endocrinol Metab. 2012;97:380-383.
46. Cook DM, Rose SR. A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary. 2012;15:301-310.
47. Wilson TA, Rose SR, Cohen P, et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr. 2003;143:415-421.
48. Elder DA, D'Alessio DA, Eyal O, et al. Abnormalities in glucose tolerance are common in children with Fanconi anemia and associated with impaired insulin secretion. Pediatr Blood Cancer. 2008;51:256-260.
49. Morrell D, Chase CL, Kupper LL, Swift M. Diabetes mellitus in ataxia-telangiectasia, Fanconi anemia, xeroderma pigmentosum, common variable immune deficiency, and severe combined immune deficiency families. Diabetes. 1986;35:143-147.
50. Polgreen LE, Thomas W, MacMillan ML, Wagner JE, Moran A, Petryk A. First phase insulin release and glucose tolerance in children with Fanconi anemia after hematopoietic cell transplantation. Pediatr Blood Cancer. 2009;53:191-196.
51. Li J, Sipple J, Maynard S, et al. Fanconi anemia links reactive oxygen species to insulin resistance and obesity. Antioxid Redox Signal. 2012;17:1083-1098.
52. Pagano G, Youssoufian H. Fanconi anaemia proteins: major roles in cell protection against oxidative damage. BioEssays. 2003;25:589-595.
53. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med. 1996;20:463-466.
54. Sigfrid LA, Cunningham JM, Beeharry N, et al. Antioxidant enzyme activity and mRNA expression in the islets of Langerhans from the BB/S rat model of type 1 diabetes and an insulin-producing cell line. J Mol Med (Berl). 2004;82:325-335.
55. Eyal O, Blum S, Mueller R, Smith FO, Rose SR. Improved growth velocity during thyroid hormone therapy in children with Fanconi anemia and borderline thyroid function. Pediatr Blood Cancer. 2008;51:652-656.
56. Rose SR, Lustig RH, Pitukcheewanont P, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab. 1999;84:4472-4479.
57. Rose SR. Improved diagnosis of mild hypothyroidism using time-of-day normal ranges for thyrotropin. J Pediatr. 2010;157:662-667; 667.e1.
58. Sherafat-Kazemzadeh R, Mehta SN, Care MM, Kim MO, Williams DA, Rose SR. Small pituitary size in children with Fanconi anemia. Pediatr Blood Cancer. 2007;49:166-170.
59. Trivin C, Gluckman E, Leblanc T, Cousin MN, Soulier J, Brauner R. Factors and markers of growth hormone secretion and gonadal function in Fanconi anemia. Growth Horm IGF Res. 2007;17:122-129.
60. Lamine F, Turki Z, Mrad R, et al. Growth hormone deficiency and pituitary stalk interruption in Fanconi anemia [in French]. Ann Endocrinol (Paris). 2008;69:63-68.
61. Massa GG, Heinrichs C, Vamos E, Van Vliet G. Hypergonadotropic hypogonadism in a boy with Fanconi anemia with growth hormone deficiency and pituitary stalk interruption. J Pediatr. 2002;140:277.
62. Alter BP, Frissora CL, Halpérin DS, et al. Fanconi's anaemia and pregnancy. Br J Haematol. 1991;77:410-418.
63. Nabhan SK, Bitencourt MA, Duval M, et al. Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients. Haematologica. 2010;95:1783-1787.
64. Larder R, Chang L, Clinton M, Brown P. Gonadotropin-releasing hormone regulates expression of the DNA damage repair gene, Fanconi anemia A, in pituitary gonadotroph cells. Biol Reprod. 2004;71:828-836.
65. Cheng NC, van de Vrugt HJ, van der Valk MA, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet. 2000;9:1805-1811.
66. Nadler JJ, Braun RE. Fanconi anemia complementation group C is required for proliferation of murine primordial germ cells. Genesis. 2000;27:117-123.
67. Sklavos MM, Giri N, Stratton P, Alter BP, Pinto LA. Anti-Müllerian hormone deficiency in females with Fanconi anemia. J Clin Endocrinol Metab. 2014;99:1608-1614.
68. Stewart J, Turner KJ. Inhibin B as a potential biomarker of testicular toxicity. Cancer Biomark. 2005;1:75-91.
69. Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med. 2003;348:908-917.
70. Rose SR, Rutter MM, Mueller R, et al. Bone mineral density is normal in children with Fanconi anemia. Pediatr Blood Cancer. 2011;57:1034-1038.
71. Petryk A, Polgreen LE, Barnum JL, Zhang L, Hodges JS, Baker KS, Wagner JE, Steinberger J, MacMillan ML. Bone mineral density in children with Fanconi anemia after hematopoietic cell transplantation [published online January 12, 2015]. Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2015.01.002.
72. Zemel BS, Leonard MB, Kelly A, et al. Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab. 2010;95:1265-1273.
73. Polgreen LE, Rudser K, Deyo M, Smith A, Baker KS, Petryk A. Changes in biomarkers of bone resorption over the first six months after pediatric hematopoietic cell transplantation. Pediatr Transplant. 2012;16:852-857.
74. Petryk A, Bergemann TL, Polga KM, et al. Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab. 2006;91:899-905.
75. Pulsipher MA, Skinner R, McDonald GB, et al. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant. 2012;18:334-347.
76. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53-58.
77. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
78. Grigg AP, Shuttleworth P, Reynolds J, et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2006;91:3835-3843.
79. Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Välimäki MJ. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab. 2005;90:3877-3885.
80. Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;4:CD005324.
81. Baim S, Leonard MB, Bianchi ML, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom. 2008;11:6-21.
82. Gordon CM, Bachrach LK, Carpenter TO, et al. Dual energy x-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom. 2008;11:43-58.
83. Ward LM, Petryk A, Gordon CM. Use of bisphosphonates in the treatment of pediatric osteoporosis. Int J Clin Rheumatol. 2009;4:657-672.